Absence of GAPDH regulation in tumor-cells of different origin under hypoxic conditions in - Vitro

BMC Research Notes

Volumn 2, Issue , 2009, Pages

  Said, Harun M ^a   Polat, Buelent ^a   Hagemann, Carsten ^a   Anacker, Jelena ^a   Flentje, Michael ^a   Vordermark, Dirk ^a,b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70349780301     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-2-8     Document Type: Article

References (48)

1. New insights into an old protein: the functional diversity of mammalian glyceraldehyde-3-phosphate dehydrogenase. MA Sirover, Biochim Biophys Acta 1999 1432 159 84 10407139
2. Identification of an additional hypoxia responsive element in the glyceraldehyde-3-phosphate dehydrogenase gene promoter. S Lu X Gu S Hoestje DE Epner, Biochim Biophys Acta 2002 1574 152 6 11955624
3. An insulin response element in the glyceraldehyde-3-phosphate dehydrogenase gene binds a nuclear protein induced by insulin in cultured cells and by nutritional manipulations in vivo. N Nasrin L Ercolani M Denaro XF Kong I Kang M Alexander, Proc Natl Acad Sci USA 1990 87 5273 7 2164673 10.1073/pnas.87.14.5273
4. Coordinated induction of two unrelated glucose-regulated protein genes by a calcium ionophore: human BiP/GRP78 and GAPDH. CC Chao WC Yam S Lin-Chao, Biochem Biophys Res Commun 1990 171 431 8 10.1016/0006-291X(90)91411-K 2118350
5. Regulation of endothelial cell glyceraldehyde-3-phosphate dehydrogenase expression by hypoxia. KK Graven RF Troxler H Kornfeld MV Panchenko HW Farber, J Biol Chem 1994 269 24446 53 7929107
6. Response of the plasma hypoxia marker osteopontin to in vitro hypoxia in human tumor cells. HM Said A Katzer M Flentje D Vordermark, Radiother Oncol 2005 76 200 5 10.1016/j.radonc.2005.06.023 16024111
7. Hypoxia-associated proteins. KK Graven HW Farber, New Horiz 1995 3 208 18 7583162
8. Hypoxic regulation of endothelial glyceraldehyde-3-phosphate dehydrogenase. KK Graven RJ McDonald HW Farber, Am J Physiol 1998 274 347 55 9486123
9. Endothelial cell hypoxic stress proteins. KK Graven HW Farber, J Lab Clin Med 1998 132 456 63 10.1016/S0022-2143(98)90122-6 9851734
10. Direct comparison of GAPDH, beta-actin, cyclophilin, and 28S rRNA as internal standards for quantifying RNA levels under hypoxia. H Zhong JW Simons, Biochem Biophys Res Commun 1999 259 523 6 10.1006/bbrc.1999.0815 10364451
11. Identification of an oxygen responsive enhancer element in the glyceraldehyde-3-phosphate dehydrogenase gene. KK Graven Q Yu D Pan JS Roncarati HW Farber, Biochim Biophys Acta 1999 1447 208 18 10542317
12. Hypoxia increases glyceraldehyde-3-phosphate dehydrogenase transcription in rat alveolar epithelial cells. B Escoubet C Planes C Clerici, Biochem Biophys Res Commun 1999 266 156 61 10.1006/bbrc.1999.1798 10581182
13. Potentiation of angiogenic response by ischemic and hypoxic preconditioning of the heart. N Maulik DK Das, J Cell Mol Med 2002 6 13 24 10.1111/j.1582-4934.2002.tb00308.x 12003666
14. HIF-1 and p53: communication of transcription factors under hypoxia. T Schmid J Zhou B Brune, J Cell Mol Med 2004 8 423 31 10.1111/j.1582-4934.2004. tb00467.x 15601571
15. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. CT Supuran, Nat Rev Drug Discov 2008 7 2 168 81 10.1038/nrd2467 18167490
16. Cell death mechanisms in neurodegeneration. KA Jellinger, J Cell Mol Med 2001 5 1 17 10.1111/j.1582-4934.2001.tb00134.x 12067447
17. Human glyceraldehyde-3-phosphate dehydrogenase in man-rodent somatic cell hybrids. GA Bruns PS Gerald, Science 1976 192 54 6 10.1126/science.176725 176725
18. How to overcome (and exploit) tumor hypoxia for targeted gene therapy. O Greco B Marples MC Joiner SD Scott, J Cell Physiol 2003 197 312 25 10.1002/jcp.10374 14566961
19. Hypoxia: The tumor's gateway to progression along the angiogenic pathway. C Brahimi-Horn E Berra J Pouyssegur, Trends Cell Biol 2001 11 32 36 10.1016/S0962-8924(01)02126-2 11684440
20. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcritpional activation pathway. A Rapisarda B Uranchimeg DA Scudiero M Selby EA Sausville RH Shoemaker G Melillo, Cancer Res 2002 62 4316 24 12154035
21. Distinct patterns of hypoxic expression of carbonic anhydrase IX (CA IX) in human malignant glioma cell lines. HM Said A Staab C Hagemann GH Vince A Katzer M Flentje D Vordermark, J Neurooncol 2007 81 27 38 10.1007/s11060-006- 9205-2 16944313
22. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. D Hanahan J Folkman, Cell 1996 86 353 64 10.1016/S0092-8674(00) 80108-7 8756718
23. Hypoxia is a strong inducer of vascular endothelial growth factor mRNA expression in the heart. A Ladoux C Frelin, Biochem Biophys Res Commun 1993 195 1005 10 10.1006/bbrc.1993.2144 8373380
24. Abscence of GAPDH regulation in human brain tumors under hypoxic conditions. HM Said C Hagemann J Anacker B Schoemig M Flentje A Katzer D Vordermark, FEBS J 2008 275 Suppl 1 327
25. GAPDH is not regulated in human glioblastoma in vivo or in vitro under hypoxic conditions. HM Said C Hagemann J Stojic B Schoemig GH Vince M Flentje K Roosen D Vordermark, BMC Mol Biol 2007 8 55 17597534 10.1186/1471-2199-8-55 (Pubitemid 47074149)
26. The regulated expression of erythropoietin by two human hepatoma cell lines. MA Goldberg GA Glass JM Cunningham HF Bunn, Proc Natl Acad Sci USA 1987 84 7972 6 2825172 10.1073/pnas.84.22.7972 (Pubitemid 17162815)
27. Effects of hypoxia-ischemia on GLUT1 and GLUT3 glucose transporters in immature rat brain. SJ Vannucci LB Seaman RC Vannucci, J Cereb Blood Flow Metab 1996 16 77 81 10.1097/00004647-199601000-00009 8530559
28. Cell type-specific association of hypoxia-inducible factor-1 (HIF-1) protein accumulation and radiobiologic tumor hypoxia. D Vordermark A Katzer K Baier P Kraft M Flentje, Int J Radiat Onco Biol Phys 2004 58 1242 50 10.1016/j.ijrobp.2003.11.030 (Pubitemid 38314810)
29. Characterization of carbonic anhydrase IX (CA IX) as an endogenous marker of chronic hypoxia in live human tumor cells. D Vordermark A Kaffer S Riedl A Katzer M Flentje, Int J Radiat Oncol Biol Phys 2005 61 1197 207 15752902
30. Expression patterns of the hypoxia-related genes osteopontin, CA9erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. HM Said C Hagemann A Staab J Stojic S Kühnel GH Vince M Flentje K Roosen D Vordermark, Radiother, Oncol 2007 83 398 405 10.1016/j.radonc.2007.05.003 (Pubitemid 46907985)
31. Oxygen-dependent regulation of NDRG1 in human glioblastoma cells in vitro and in vivo. HM Said S Stein C Hagemann B Polat A Staab J Anacker B Schoemig M Theobald M Flentje D Vordermark, Oncol Rep 2009 21 237 246 19082468
32. Rapid detection of the hypoxia regulated CA-IX and NDRG1 gene expression in different glioblatoma cells in vitro. HM Said B Polat A Staab C Hagemann S Stein M Flentje M Theobald A Katzer D Vordermark, Oncol Rep 2008 20 413 419 18636206
33. Identification of an additional hypoxia responsive element in the glyceraldehyde-3-phosphate dehydrogenase gene promoter. S Lu X Gu S Hoestje DE Epner, Biochim Biophys Acta 2002 1574 152 6 11955624
34. Epigenetic regulation of gene expression in cervical cancer cells by the tumor microenvironment. N Denko C Schindler A Koong K Laderoute C Green A Giaccia, Clin Cancer Res 2000 6 480 7 10690527
35. The cytotoxicity of chemotherapy drugs varies in cervical cancer cells depending on the p53 status. R Koivusalo S Hietanen, Cancer Biol Ther 2004 3 1177 83 15640620
36. 2+ exchanger. R Yamaji K Fujita S Takahashi H Yoneda K Nagao W Masuda M Naito T Tsuruo K Miyatake H Inui Y Nakano, Biochim Biophys Acta 2003 1593 269 76 10.1016/S0167-4889(02)00397-X 12581871
37. Accumulation and nuclear import of HIF1 during high and low oxygen concentration in skeletal muscle cells in primary culture. HP Kubis N Hanke RJ Scheibe G Gros, Biochim Biophys Acta 2005 1745 187 95 15967517
38. Modulation of bovine articular chondrocyte gene expression in vitro by oxygen tension. MJ Grimshaw RM Mason, Osteoarthritis Cartilage 2001 9 357 64 10.1053/joca.2000.0396 11399100
39. Therapeutic efficacy of PUMA for malignant glioma cells regardless of p53 status. H Ito T Kanzawa T Miyoshi S Hirohata S Kyo A Iwamaru H Aoki Y Kondo S Kondo, Hum Gene Ther 2005 16 685 98 15960600 10.1089/hum.2005.16.685 (Pubitemid 40864269)
40. Mutations of the BRAF gene in human cancer. H Davies GR Bignell C Cox P Stephens S Edkins S Clegg J Teague H Woffendin MJ Garnett W Bottomley N Davis E Dicks R Ewing Y Floyd K Gray S Hall R Hawes J Hughes V Kosmidou A Menzies C Mould A Parker C Stevens S Watt S Hooper R Wilson H Jayatilake BA Gusterson C Cooper J Shipley D Hargrave K Pritchard-Jones N Maitland G Chenevix-Trench GJ Riggins DD Bigner G Palmieri A Cossu A Flanagan A Nicholson JW Ho SY Leung ST Yuen BL Weber HF Seigler TL Darrow H Paterson R Marais CJ Marshall R Wooster MR Stratton PA Futreal, Nature 2002 417 949 54 10.1038/nature00766 12068308
41. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. N Ishii D Maier A Merlo M Tada Y Sawamura AC Diserens EG Van Meir, Brain Pathol 1999 9 469 79 10416987
42. pp90RSK- and protein kinase C-dependent pathway regulates p42/44MAPK-induced LDL receptor transcription in HepG2 cells. GS Kapoor C Golden B Atkins KD Mehta, J Lipid Res 2003 44 3 584 93 10.1194/jlr.M200302-JLR200 12562867
43. Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines. A Puisieux K Galvin F Troalen B Bressac C Marcais E Galun F Ponchel C Yakicier J Ji M Ozturk, FASEB J 1993 7 14 1407 13 8224613
44. Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line. KT Chan ML Lung, Cancer Chemother Pharmacol 2004 53 6 519 26 10.1007/s00280-004-0767-4 15004724
45. Non-immunogenic murine hepatocellular carcinoma Hepa1-6 cells expressing the membrane form of macrophage colony stimulating factor are rejected in vivo and lead to CD8+ T-cell immunity against the parental tumor. Q Dan H Trinh CC Williams C Lloyd HT Wepsic EW Jeffes MR Jadus, Mol Ther 2001 4 5 427 37 10.1006/mthe.2001.0477 11708879
46. Ras mutation, irrespective of cell type and p53 status, determines a cell's destiny to undergo apoptosis by okadaic acid, an inhibitor of protein phosphatase 1 and 2A. D Rajesh K Schell AK Verma, Mol Pharmacol 1999 56 3 515 25 10462539
47. Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair. M Toulany U Kasten-Pisula I Brammer S Wang J Chen K Dittmann M Baumann E Dikomey HP Rodemann, Clin Cancer Res 2006 12 13 4119 26 10.1158/1078-0432.CCR-05-2454 16818713
48. Four human carcinoma cell lines with novel mutations in position 12 of c-K-ras oncogene. DM Valenzuela J Groffen, Nucleic Acids Res 1986 14 2 843 52 3945555 10.1093/nar/14.2.843